Abstract
With the widening gap between medicines demand and local supply, the African medicines market currently presents relevant investment opportunities for foreign stakeholders. Its attractiveness is, however, challenged by some of Africa’s endemic features, such as inadequate local health infrastructure, fragmented regulatory systems and the inability to handle direct aid from the international community. Against this backdrop, the ongoing harmonization process and the introduction of the African Medicines Agency in 2019 have been particularly welcomed and received international support, especially from China and the EU. This paper, after outlining the initiatives taken within the African harmonization process, takes a comparative look at the actions taken by China and the EU and attempts to indicate which initiatives have proved to be and will be most useful to AMA establishment and African regulatory stability in the prospect of investment attraction.
Cite As: Roberto Isibor and Caterina Coroneo, The Future of African Pharmaceutical Market Harmonization: A Compared Analysis Between the European and Chinese Approach to African Medicines Agency Establishment, Volume 6, Issue 1, AfJIEL (2026).